Who is sponsoring NCT02338037?

NCT02338037 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT02338037?

Interventions in NCT02338037: Therapeutic Conventional Surgery, Biopsy, Eribulin Mesylate, Microdialysis, Pharmacological Study.

Is NCT02338037 still recruiting?

NCT02338037 is currently completed. Last updated 19 March 2024.

Last reviewed 2024-03-19 · How we verify

NCT02338037

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Completed EARLY_PHASE1 Last updated 19 March 2024

What this trial tests

EARLY_PHASE1 trial testing Therapeutic Conventional Surgery in Metastatic Malignant Neoplasm in the Adult Brain in 8 participants. Completed in 15 March 2024.

Timeline

19 May 2015

Primary endpoint
4 August 2017

15 March 2024

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	19 May 2015
Primary completion	4 August 2017
Estimated completion	15 March 2024
Sites	1 location across United States

Drugs / interventions tested

Therapeutic Conventional Surgery
Biopsy — full drug profile →
Eribulin Mesylate — full drug profile →
Microdialysis
Pharmacological Study — full drug profile →

Conditions studied

Metastatic Malignant Neoplasm in the Adult Brain — all drugs for Metastatic Malignant Neoplasm in the Adult Brain →
Primary Brain Tumor — all drugs for Primary Brain Tumor →

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Metastatic Malignant Neoplasm in the Adult Brain or Primary Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot trial studies the brain concentration of eribulin mesylate in treating patients with primary or metastatic brain tumors. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Collecting small samples of brain fluids may help determine how well eribulin mesylate concentrates into the brain tumor.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Eribulin in Cancer Treatment.
Swami U, Shah U, Goel S. · · 2015 · cited 46× · PMID 26262627 · DOI 10.3390/md13085016
An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.
Eroglu Z, Synold T, Badie B, Liu A, et al · · 2024 · cited 1× · PMID 39422741 · DOI 10.1007/s00280-024-04711-2

Verify or expand the search:

Other trials of Therapeutic Conventional Surgery

Trials testing the same drug.

NCT04199026 — Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sa · NA · recruiting
NCT05316688 — A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavit · Phase 1, PHASE2 · terminated
NCT04870034 — Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic C · EARLY_PHASE1 · withdrawn
NCT05030298 — Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial · Phase 1 · recruiting
NCT04871529 — Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior t · Phase 2 · terminated

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02338037 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 19 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02338037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing